Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Freeline Therapeutics Holdings plc
Spur Therapeutics Announces Positive Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Gene Therapy Candidate for Gaucher Disease, at WORLDSymposium™
04 févr. 2025 08h00 HE
|
Spur Therapeutics
Spur Therapeutics Announces Positive Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Gene Therapy Candidate for Gaucher Disease, at WORLDSymposium
Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease
03 févr. 2025 08h00 HE
|
Spur Therapeutics
Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease
Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium
23 janv. 2025 08h00 HE
|
Spur Therapeutics
Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium
Spur Therapeutics Announces Development Candidate in Parkinson’s Disease Gene Therapy Program
03 déc. 2024 07h00 HE
|
Spur Therapeutics
Spur Therapeutics Announces Development Candidate in Parkinson’s Disease Gene Therapy Program
Spur Therapeutics to Participate in Upcoming Investor Conferences
19 nov. 2024 08h00 HE
|
Spur Therapeutics
Spur Therapeutics to Participate in Upcoming Investor Conferences
Spur Therapeutics to Participate in B. Riley Securities’ Next-Gen Tissue Delivery Modalities Virtual Summit
07 nov. 2024 08h00 HE
|
Spur Therapeutics
Spur Therapeutics to Participate in B. Riley Securities’ Next-Gen Tissue Delivery Modalities Virtual Summit
Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for SBT101, its Gene Therapy Candidate in Adrenomyeloneuropathy (AMN)
31 oct. 2024 08h00 HE
|
Spur Therapeutics
Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for SBT101, its Gene Therapy Candidate in Adrenomyeloneuropathy (AMN)
Spur Therapeutics Showcases Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Oral Presentation at ESGCT 31st Annual Congress
23 oct. 2024 02h00 HE
|
Spur Therapeutics
Spur Therapeutics Showcases Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease
Spur Therapeutics Announces Oral Presentation Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
03 oct. 2024 08h00 HE
|
Spur Therapeutics
LONDON, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Spur Therapeutics, formerly Freeline Therapeutics, today announced that it will present updated clinical data from its GALILEO-1 first-in-human clinical...
Spur Therapeutics to Participate in Chardan’s 8th Annual Genetic Medicines Conference
23 sept. 2024 08h00 HE
|
Spur Therapeutics
Spur Therapeutics to Participate in Chardan’s 8th Annual Genetic Medicines Conference